22 results
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
6 Aug 24
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
4:10pm
.
GAAP research and development (R&D) expenses were $29.1 million for the quarter ended June 30, 2024, as compared to $18.0 million for the quarter … ended June 30, 2023. The increase in R&D expenses was primarily related to increased spending on clinical development activities as we continue
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
8 May 24
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
earned from marketable securities.
GAAP research and development (R&D) expenses were $29.9 million for the quarter ended March 31, 2024, as compared … to $22.8 million for the quarter ended March 31, 2023. The increase in R&D expenses was primarily related to a $5.0 million milestone payment incurred
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
11 Mar 24
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
4:05pm
year 2023 was primarily due to higher interest income earned from marketable securities.
GAAP research and development (R&D) expenses were $25.9 … and year ended December 31, 2022, respectively. The increase in
R&D expenses was primarily a result of increased spending on clinical operations
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
7 Nov 23
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:10pm
clinical trials.
GAAP research and development (R&D) expenses were $19.5 million for the quarter ended September 30, 2023, as compared to $17.6 … activities as Olema continues to advance palazestrant into late-stage clinical development.
Non-GAAP R&D expenses were $16.7 million for the quarter
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
8 Aug 23
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:09pm
development.
GAAP research and development (R&D) expenses were $18.0 million for the quarter ended June 30, 2023, as compared to $27.1 million … by increased spending on clinical operations-related activities as we continue to advance palazestrant into late-stage clinical trials.
Non-GAAP R&D expenses
8-K
EX-99.1
cv4zymy4
9 May 23
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-99.1
686e6k6aetiw8h96
8 Nov 22
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:42pm
8-K
EX-99.1
smd5g7a
9 Aug 22
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
103o5nrhglsns4r
9 May 22
Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:41pm
8-K
EX-99.1
ca3ll2 3f
28 Feb 22
Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
4:39pm
8-K
EX-99.1
7df01ayickvwr07gdzqd
10 Nov 21
Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:19pm
8-K
EX-99.1
4j1n 9zey
10 Aug 21
Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:16pm
10-Q
oieqcnt8mdrexob80tde
11 May 21
Quarterly report
4:22pm
8-K
EX-99.1
sn1t7z452mg2
11 May 21
Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:19pm